Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
GABA (gamma-aminobutyric acid) is a neurotransmitter that acts as an inhibitory chemical messenger in the central nervous system. It functions by binding to specific receptors in the brain, reducing neuronal activity and promoting relaxation. GABA is used in the treatment of various disease indications, including anxiety disorders such as generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. It is also utilized as a natural sleep aid to alleviate insomnia symptoms and improve sleep quality. According to the World Health Organization (WHO), anxiety disorders affect approximately 3.6% of the global population, with Europe and the United States experiencing similar prevalence rates. In Europe, it is estimated that around 60 million individuals are affected by anxiety disorders. In the United States, anxiety disorders are the most common mental illnesses, affecting approximately 40 million adults. Insomnia, another indication for GABA, affects about 30% of the European population and over 35% of adults in the United States, as reported by WHO.
The growth of the GABA market is driven by several factors, including the increasing awareness among consumers about the benefits of GABA in promoting relaxation and reducing anxiety and sleep-related issues. Companies such as Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Balance Therapy, Allos Pharma, Cerevel Therapy, UCB, Roche, Nobias Therap, Bausch Health, Royalty, RVL Pharma, Neurelis, Marinus, Asarina Pharma, Aquestive, Remedica, Acorda, XWPharma, BioLineRx, Takeda, and J&J cater this category. Moreover, many companies are coming up with new molecules in this space. For instance, UCB is one such company that is currently conducting a clinical trial of the drug AZ022 for the treatment of epilepsy.
GABA Market Key Developments:
Approved GABA molecules
GABA Pipeline Molecules
Clinical Activity and Development of GABA
In the GABA space, more than 20 companies are conducting >200 clinical trials in this category of drugs. For instance,
Product Name |
Total Studies |
Ciprofol injectable emulsion (HSK3486) |
45 |
Gaboxadol (OV101) |
24 |
Remimazolam tosylate (HR-7056) |
21 |
BAER-101 |
16 |
Arbaclofen (STX209) |
16 |
Darigabat (CVL-865) |
15 |
Padsevonil (UCB0942) |
15 |
Basmisanil (RG1662) |
14 |
Zuranolone (SAGE-217) |
14 |
Staccato alprazolam (AZ-002) |
12 |
Arbaclofen placarbil (XP 19986) |
9 |
PRAX-114 |
7 |
Fasoracetam (NB-001) |
7 |
Pentylenetetrazole (BTD-001) |
6 |
BL-1020 |
5 |
JNJ-26489112 |
5 |
Sepranolone (UC1010) |
5 |
XW10172 |
4 |
EQU-001 |
3 |
SAGE-324 |
3 |
GABA (gamma-aminobutyric acid) is a neurotransmitter that plays a crucial role in regulating brain activity and promoting relaxation. In the context of target indications, GABA is commonly used to alleviate symptoms associated with anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. It is also utilized as a natural sleep aid to improve sleep quality and reduce insomnia symptoms. GABA's calming effects on the central nervous system make it a potential candidate for managing stress, promoting mental relaxation, and supporting overall mental well-being. Furthermore, ongoing research explores its potential therapeutic applications in conditions like epilepsy, depression, and ADHD, but further investigation is required for conclusive evidence.
Download Free Sample Report
GABA drugs are used in the management of symptoms associated with anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder.
The growth of the GABA market is driven by several factors, including the increasing awareness among consumers about the benefits of GABA in promoting relaxation and reducing anxiety and sleep-related issues.
The major players in this space are Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Balance Therapy, Allos Pharma, Cerevel Therap, UCB, Roche, Nobias Therap, Bausch Health, Royalty, RVL Pharma, Neurelis, Marinus, Asarina Pharma, Aquestive, Remedica, Acorda, XWPharma, BioLineRx, Takeda, and J&J.
The GABA market faces restraints such as limited awareness among consumers about its potential benefits and effectiveness, as well as regulatory challenges and restrictions on its use in certain regions or jurisdictions, which hinder its widespread adoption and growth. Additionally, the availability of alternative products or treatments for anxiety and sleep disorders poses a competitive challenge to the GABA market.
Key Market Players